DPX-Survivac: Phase I started

Immunovaccine began the Phase I portion of a U.S. Phase I/II trial evaluating 3 doses of subcutaneous DPX-Survivac given 3 weeks apart. The open-label Phase I portion will evaluate 0.1 and 0.5 mL DPX-...